StemVacs Cellular Immunotherapy: Positive Animal Data Reported in the 4T1 Breast Cancer Model

“The current data, which conclusively demonstrates the induction of immunological memory to cancer, as well as the natural killer cell as a mechanism of action, will position us to provide the FDA responses to their questions from our submitted IND,” said Dr. James Veltmeyer, Chief Medical Officer of the Company.